← Leaderboards
Cristina R. Ferrone
Massachusetts General Hospital
$582,381
Attributed
$997,761
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $220K · FY2013–23$250K$187.5K$125K$62.5K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$997,761 · 5
By mechanism
R03$588,813 · 4
R21$408,948 · 1
Top collaborators
- Soldano Ferrone5 shared
- Joseph Hasbrouck Schwab1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- David E Fisher$28,420,496
- Lance L Munn$15,934,149
- John R Sims$518,930
- Kenneth Stuart Cohen$649,755
- David B Sykes$998,320
Others in their field
Top investigators on “Normal Tissue Morphology”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,450,141
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
- Walter John Curran · Thomas Jefferson University$26,641,549
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$24,664,682
- Lynn Briscoe · Leidos Biomedical Research, Inc.$23,339,595
- Larry Arthur$20,205,250
Research focus
Normal Tissue MorphologyDesignCellsTumorIn VitroImmunotherapeutic AgentIn VivoTumor AntigensCombinatorialCell LineEffective TherapyResponseImmunotherapyToxic EffectTheoriesTreatment EfficacyPancreatic Ductal AdenocarcinomaCancer Stem CellPlayBaseCd276 GeneConduct Clinical TrialsMalignant NeoplasmsNeoplastic Cell
Grant awards (7)
Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells$167,000
R03 · FY2023 · CA · contact PI
B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)$167,163
R03 · FY2021 · CA
Potential role of brachyury in HLA class I antigen processing machinery component downregulation in chordoma cells$77,399
R03 · FY2020 · CA · contact PI
IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma$80,063
R03 · FY2019 · CA
IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma$97,188
R03 · FY2018 · CA
Grp94 targeted therapy for pancreatic ductal adenocarcinoma$219,995
R21 · FY2014 · CA
Grp94 targeted therapy for pancreatic ductal adenocarcinoma$188,953
R21 · FY2013 · CA